# OnCo record nct06312137 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06312137/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06312137", "NCT06312137" ;
  schema:name "A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm"@en ;
  schema:alternateName "TroFuse-019"@en ;
  schema:description "A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06312137/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06312137> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-04-03" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:companies <https://onco.cc/companies/merck/> .